Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.

High-impact 2025 analyses of the landmark FLOW trial provide critical practice-changing data on GLP-1 receptor agonists in diabetic kidney disease.